NCT03312335View on ClinicalTrials.gov

Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

December 23, 2019

Study Completion Date

December 23, 2019

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

Low-dose Aldesleukin (Proleukin®)

Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.

Trial Locations (1)

Unknown

University Hospital Zurich, Zurich

All Listed Sponsors
lead

Onur Boyman, MD

OTHER

NCT03312335 - Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter